Analysts Bullish On Crestor After Strong JUPITER Data
This article was originally published in The Pink Sheet Daily
Executive Summary
JPMorgan raises global sales estimate but cautions that AstraZeneca has under-invested in the statin.
You may also be interested in...
Chart: Inside JUPITER's Realm: A Closer Look At The Trial Results
AstraZenenca's JUPITER study pushes the boundaries of the statin class to a new level. The latest large-scale outcomes trial for the statin class, using AstraZenenca's Crestor (rosuvastatin), explores use in a population that has healthy LDL cholesterol levels but with high levels of an inflammation biomarker that predicts future cardiovascular events: high-sensitivity C-reactive protein.
Will JUPITER Change Statin Use?
Positive results from AstraZeneca’s outcomes trial of Crestor have all eyes on whether statin utilization will undergo a paradigm shift.
Will JUPITER Change Statin Use?
Positive results from AstraZeneca’s outcomes trial of Crestor have all eyes on whether statin utilization will undergo a paradigm shift.